The power of AI and medical imaging to find cancer
Lucida Medical develops software based on artificial intelligence methods (machine learning and image processing) to enable radiologists to find cancer accurately, consistently and quickly using MRI.
Pi™, our first product, is a CE-marked medical device to support the analysis of MRI for prostate cancer diagnosis. Note that while we are seeking further regulatory approvals, Pi™ is not for sale or use in the USA.
We especially welcome contact from investors and healthcare professionals interested in supporting our research, joining clinical studies, or using Pi™ in the clinic in Europe or the United Kingdom.
Ground-breaking research on AI for real-world prostate MRI
Lucida Medical CTO, Mark Hinton, will present preliminary results from our PAIR-1 research study at ECR 2022 in Vienna. This work, in partnership with Hampshire Hospitals NHS Foundation Trust, demonstrates that Pi™ can be applied to prostate MRI in routine NHS diagnostic pathways aith a range of hospitals, MRI scanners and field strengths.
Integration with EMRAD's clinical workflow
GE Healthcare and Lucida Medical have installed Pi in EMRAD’s data centre. It automatically processes every prostate MRI study, saving results to the PACS and RIS. This enables EMRAD’s NHS radiologists to report using Pi in their existing workflow.
Lucida Medical appoints Dr David Tuch as Chair to spearhead investment and growth
David joins to help the company build on tremendous progress during 2021, including a key milestone CE mark for its Pi™ software, and a successful collaboration and technology demonstration with a major vendor and radiology network. David will work with the Lucida Medical team to help secure further investment and enable the company to scale up to put its technology into the hands of clinicians….
Get in touch
To find out more, please contact us through:
Our Partners
We collaborate with Cambridge University, we are a partner in the ReIMAGINE prostate imaging trial, are in the process of establishing collaborative partnerships with several UK NHS Trust hospitals to help further develop and validate and test Pi, our AI system for detecting prostate cancer from MRI.
